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Background: Major depressive disorder (MDD) is a prevalent and severe disorder. Although effective treatments for
MDD are available, many patients remain untreated, mainly because of insufficient treatment capacities in the
health care system. Resulting waiting periods are often associated with prolonged suffering and impairment as well
as a higher risk of chronification. Web-based interventions may help to alleviate these problems. Numerous studies
provided evidence for the efficacy of web-based interventions for depression. The aim of this study is to evaluate a
new web-based guided self-help intervention (GET.ON-Mood Enhancer-WL) specifically developed for patients
waiting to commence inpatient therapy for MDD.
Methods: In a two-armed randomised controlled trial (n = 200), the web-based guided intervention GET.ON-Mood
Enhancer-WL in addition to treatment as usual (TAU) will be compared with TAU alone. The intervention contains
six modules (psycho education, behavioural activation I & II, problem solving I & II, and preparation for subsequent
inpatient depression therapy). The participants will be supported by an e-coach, who will provide written feedback
after each module. Inclusion criteria include a diagnosis of MDD assessed with a structured clinical interview [SCID] and
a waiting period of at least three weeks before start of inpatient treatment. The primary outcome is observer-rated
depressive symptom severity (HRSD24). Further (explorative) questions include whether remission will be achieved
earlier and by more patients during inpatient therapy because of the web-based preparatory intervention.
Discussion: If GET.ON-Mood Enhancer-WL is proven to be effective, patients may start inpatient therapy with reduced
depressive symptom severity, ideally leading to higher remission rates, shortened inpatient therapy, reduced costs, and
decreased waiting times.
Trial registration: German Clinical Trial Registration (DRKS): DRKS00004708.
Keywords: Internet therapy, Waiting time, Major depression, Inpatient treatment, RemissionBackground
Major depressive disorder (MDD) is one of the most
prevalent psychiatric disorders, with a lifetime preva-
lence that is currently estimated at about 16% [1-3] and
predicted to further increase in the foreseeable future
[4,5]. By 2030, depressive disorders are anticipated to be
responsible for the highest disease burden in high-* Correspondence: reins@inkubator.leuphana.de
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stated.income countries among all diseases [6]. Suffering from
MDD is accompanied by a substantial loss in quality of
life, not only for patients but also for their relatives
[7-9]. Furthermore, suffering from a depressive episode
is associated with a high risk of relapse and recurrence
[1,10] as well as a chronic course [11], increased mortal-
ity rates [12], significant disability, high medical service
use, and major economic costs [13-16].
Although numerous studies provide evidence for the
efficacy of available psychological and pharmacological
treatments [17,18], many individuals remain untreatedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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First, individuals who likely to benefit from treatment do
not seek treatment because they lack knowledge on
available treatment options, anticipate negative (social)
consequences, live in underserved areas, fear prohibitive
costs, or prefer self-help [20]. Limited availability of cli-
nicians and difficulties in attending therapy during usual
business hours are further barriers [21]. Second, those
who do seek help rarely receive immediate access to
treatment due to long waiting lists for both inpatient
and outpatient psychotherapy [20,22]. Consequently,
people with an urgent need for therapy are left alone
with their burden, which poses several ethical, practical,
and therapeutic problems. In addition to high levels of
suffering, long waiting times might increase symptom
severity and hence increase the need for more intense
and longer treatments [23,24].
Another related problem is that because of factors
such as limited financial resources and time, inpatient
patients are often discharged from the clinic at a very
early stage, leaving them with substantial residual symp-
toms. However, even low levels of residual symptoms are
known to increase the risk for relapse and recurrence
[25-28]. Recent meta-analyses show that between 40 and
60% of patients with MDD relapse after the initial re-
sponse to an acute-phase treatment [27].
The use of the internet to provide guided self-help might
contribute to solving these problems. First, meta-analytical
evidence has shown comparable effects of such inter-
ventions compared to traditional psychological treatments
when there is at least some support from a professional
[29-31]. Furthermore, web-based interventions may repre-
sent a far-reaching method for supporting patients during
the waiting time for psychotherapy [32].
This method has been well accepted by patients and
shown to be effective in the acute treatment phase as
well as the maintenance phase [33-37]. The adaptation
of internet-based strategies for the waiting phase has
several advantages: (a) patients can begin their treatment
immediately with no additional waiting time; (b) the on-
line program can be used 24 hours a day, independent
of office hours, every day of the week; (c) the material
can be reviewed as often as needed; (d) the patient can
use it in a familiar environment, without any time or
travel costs, which allows for privacy and consistency of
care [34,38,39]; and (e) web-based interventions can help
patients to practise skills that are relevant for their sub-
sequent therapy (i.e., self-monitoring, problem-solving
competencies, behavioural activation).
However, to the best of our knowledge, only one study
has evaluated the use of internet-based guided self-help
for patients on a waitlist for psychotherapy [40]. In this
non-randomised observational study, the researchers
found large and significant between-group effect sizes foronline treatment for depression (d = 0.94) compared to a
waiting control group after five weeks. The majority of eli-
gible patients preferred the web-based problem-solving
therapy instead of waiting for face-to-face treatment. Par-
ticipation in this intervention increased the speed of
improvement for symptoms of depression during the fol-
lowing therapy [40].
Given the high level of suffering from a depressive epi-
sode and the limited availability of psychotherapy re-
sources, new and innovative approaches are needed to
address the long waiting times. Using waiting times ef-
fectively by providing patients with evidence-based
guided self-help methods might result in higher remis-
sion rates at the end of inpatient treatment or an earlier
remission, thereby reducing costs.
Trial objectives and purpose
The aim of this multi-centre randomised controlled trial is
to evaluate whether a newly developed web-based guided
self-help intervention (GET.ON-Mood Enhancer-WL) is
effective in reducing depressive symptom severity in pa-
tients waiting for inpatient therapy when compared to
treatment-as-usual. Moreover, it will be explored whether
participants would respond or achieve remission earlier in
the course of the subsequent inpatient therapy and would




In this two-armed randomised controlled trial, we will
compare GET.ON-Mood Enhancer-WL combined with
TAU to TAU alone. The target group will consist of indi-
viduals (n = 200) who have been referred to inpatient
treatment of major depressive disorder by their general
practitioner, psychotherapist, or psychiatrist and are await-
ing inpatient therapy in one of the German study clinics
(Schön Klinik Bad Arolsen/Bad Staffelstein/Bad Bram-
stedt). The study will be implemented as part of the rou-
tine mental health service of the study clinics. Primary and
secondary outcome measures will be assessed at baseline,
post-treatment (three weeks), at intake for inpatient ther-
apy, weekly during inpatient therapy, and after inpatient
therapy. Table 1 gives an overview of the assessments at
all planned time points.
All procedures were approved by the ethics committee
at the Philipps University of Marburg in November 2012
(reference number: 2012-37kr). The trial is registered at
the German Clinical Trial Register (DRKS00004708).
Inclusion and exclusion criteria
Patients will be included in this trial when they (a) are
awaiting to be treated with routine mental health care at
any of the three study centres, (b) are scheduled to have
Table 1 Overview of assessments

























16 X X X
PHQ-9 depressive symptoms 9 X X X X X X X X X X X
Penn State-worry
questionnaire–short version
worrying 3 X X X
BA-DS–short version behavioural activation 9 X X X
Social problem solving
inventory–short version
problem solving 10 X X X
EuroQoL life quality 5 X X X
Brief scale for measuring






PATHEV therapy expectations 11 X X X
HAQ help alliance 11 X X X
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age or older, (d) meet criteria of a major depressive epi-
sode (according to DSM-V criteria), (e) are motivated to
actively participate in the self-guided internet interven-
tion to improve their depressive mood during the wait-
ing time, (f ) have access to a computer with an internet
connection and a valid email address, and (g) return the
signed informed consent form.
We will exclude patients with bipolar disorder or acute
psychotic symptomatology (according to DSM-V cri-
teria) or patients showing a notable suicidal risk, as
assessed during the structured clinical interview.
Recruitment
Patients who apply for inpatient therapy via the clinic
website (http://www.schoen-kliniken.de/ptp/kkh/bar/
anmeldung/krankenhaus/) will be immediately in-
formed about the current trial and can sign up to re-
ceive further information. Patients who directly contact
the clinic’s head office will receive by mail an informa-
tion letter that contains the hyperlink to the above-
mentioned website.
Assessment of eligibility and randomisation
After signing up for further information via the website,
prospective participants will receive an email from the
research team that includes detailed information about
the study. They will be asked to send back an informedconsent form via e-mail if they are willing to participate.
Patients providing informed consent will be interviewed
by telephone to clarify whether they fulfill the inclusion
criteria. These structured clinical interviews for DSM dis-
orders (SCID) will be conducted by psychotherapists-in-
training who will be weekly supervised by an experienced
clinician. Participants providing informed consent, meet-
ing all of the inclusion and none of the exclusion criteria
will enter the study. They will be randomly allocated to
treatment conditions and complete initial assessment. The
allocation will be performed by an independent researcher
not otherwise involved in the study using an automated,
computer-based random integer generator (randlist). The
allocation will be concealed in advance from the partici-
pants, researchers involved in recruitment, and inpatient
therapists. Patients will be informed that they can with-
draw from the study at any time, without any conse-
quences for their subsequent treatment. See Figure 1 for
participants’ flow throughout the study.Assessments
Self-report and observer-rated assessments will take
place at baseline, post-intervention (three weeks after
randomisation), at intake for inpatient treatment,
weekly during inpatient therapy, and after completion
of inpatient therapy (see Figure 1 and Table 1 for a de-
tailed overview). Self-report data will be collected using
a secure web-based assessment system (AES, 256-bit
Figure 1 Study flow diagram.
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conducted via the telephone by trained interviewers.
Observer-rated assessments will be recorded to examine
interrater reliability. In cases of disagreement, the two
raters will discuss until a consensus is formed, and the rat-
ing agreed upon will be used for further analyses. If no
agreement is reached after discussion, the assessment will
be rated by an experienced diagnostic rater, and this rating
will be used for analysis.
Blinding
The research staff conducting the observer-based rating of
depressive symptoms will be blinded to the participants’
assigned conditions. Considerable effort is being under-
taken to ensure blindness, including the following: (a) an
explanation to the participants as to why it is important
not to inform the interviewer about the condition to
which they were assigned, (b) a written reminder in the
interview manual prompting the interviewer to ask the
participant not to inform him or her about the randomisa-
tion status, (c) verbal reminders to the patient before the
interview, and (d) a documentation after the assessment ofwhether or not the interviewer is still blind to the treat-
ment condition. If the interviewer finds out about the
treatment condition another independent interviewer will
conduct the interview instead. Participants will not be
blinded to the treatment condition.
Interventions
GET.ON-Mood Enhancer-WL–experimental group
The primary purpose of the web-based intervention (GET.
ON-Mood Enhancer-WL) is to reduce depressive symp-
tomatology prior to intake for inpatient treatment. In
addition GET.ON-Mood Enhancer-WL aims to prepare
patients for subsequent inpatient therapy by providing
relevant information (psycho education) and using effect-
ive and well known elements that are mainly based on be-
havioural therapy and problem-solving therapy. Abundant
evidence exists to support components such as psycho
education [18,35], behavioural activation [41,42], and prob-
lem solving [43,44] in the treatment of major depression.
A previous meta-regression analysis examining the re-
lationship of treatment intensity to treatment outcome
in the treatment of depression indicated that more fre-
quent therapy sessions may be associated with a better
outcome compared to less frequent sessions [45]. Thus,
we included six modules and advised participants to
complete at least one, but preferably two, lessons per
week. In all, the training lasts approximately three
weeks. We will not include more modules because (a) a
recent meta-analysis [46] found web-based interventions
for depression including more than seven modules to be
less effective (d = 0.36) than interventions with seven or
fewer modules (d = 0 .75) and (b) we wanted to lower
the threshold for individuals as much as possible. Table 2
gives an overview of the sessions and their content.
Given the fact that some studies show a better effect for
interventions with at least a low level of guidance com-
pared to unguided interventions [46-48], this strategy
might be a promising approach to encourage high treat-
ment adherence. Therefore GET.ON-Mood Enhancer-WL
provides a low level of guidance, including individualised
feedback for the patient after finishing each of the six ses-
sions. This feedback will be given by psychotherapists-in-
training who will receive weekly supervision by an experi-
enced clinician. After completion of the program, there
will be no further guidance provided, but the patient will
be free to continue with the program or to repeat the
exercises.
Some studies have found that highly interactive inter-
ventions are more engaging, create higher expectations for
improvement, and promote increased motivation and sat-
isfaction in general [49,50]. Hence, the program contains
several interactive components for the patients, including
a diary to rate their mood and activity level, videos, testi-
monials, exercises, homework exercises, optional modules,




First, patients should learn about their disease
(symptoms, causes, and types of depression).
In addition, the role of motivation in getting
through this program should be emphasised.
Sessions 2 and 3:
behavioural activation
Second, two behavioural activation sessions
will teach the patient about the association
between activity and mood. Thus, positive
activities can be planned and implemented
into the daily routine. In addition, possible
obstacles will be considered. The planning of
positive activities remains part of the
program during the subsequent sessions.
Furthermore, participants can work through
the facultative module about sleep problems.
Sessions 4 and 5:
problem-solving
techniques
Sessions 4 and 5 are concerned with
problem solving in which the patient learns
to distinguish between solvable and
unsolvable problems and practises using a
six-step plan as a tool to solve problems. In-
formation about unsolvable problems is




Finally, the patient evaluates his gains and
receives a summary of the program.
Furthermore, he is encouraged to think about
a future plan (such as choosing topics to work
on during his inpatient stay).
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(homework assignments) to integrate newly acquired
strategies and techniques into daily life. In the beginning
of each subsequent lesson, participants are invited to re-
flect on their experiences with the newly acquired skills.
The training is adaptive in a sense, as the content is tai-
lored to the specific needs of the individual participant by
continuously asking participants to respond by choosing
from various response options. Subsequent content is then
tailored to the participant’s response. Using responsive
web design, participants can follow the program on the
internet using a computer, tablet, or mobile phone. An in-
tegrated read-aloud function allows participants to follow
an audio narration of the lessons.
Treatment as usual (TAU)–control group
TAU includes a wide variety of treatment alternatives,
such as antidepressant medication, counselling, face-to-
face psychotherapy, or no treatment at all. However, to
control for potential confounding effects, treatment util-
isation as well as changes in the dose of antidepressant
medication will be closely monitored during the study
period.
Inpatient treatment–both groups
Inpatient treatment will generally base on Cognitive Be-
havioral Therapy (CBT). Patients will receive one to two
session of individual therapy (50 minutes) and an aver-
age of six sessions of group therapy (90 minutes) perweek. Interventions will be supplemented with sports-
and physiotherapy, as well as medical treatment (includ-
ing medication) when necessary. Duration of treatment
usually range between 21 and 56 days.
Sample size
This study will be designed to detect a difference of d =
0.40 between the groups as the primary outcome. As pa-
tients expect to be treated for their depression in the
subsequent inpatient psychotherapeutic treatment, we
do expect a somewhat smaller effect size for our inter-
vention than what has been found in the most recent
meta-analysis of internet-based guided self-help treat-
ments for depression [35]. With a power of 0.80 in a
two-tailed test and α = .05, a sample of n = 200 partici-
pants would need to be included at baseline (calculated
using GPower 3.1).
Primary and secondary outcomes
Primary outcome
The primary outcome is depressive symptom severity, as
measured by the Hamilton Rating Scale for Depression
(HRSD24) [51], with assessments conducted pre-and post-
treatment. The HRSD is likely the most widely used
clinician-rated scale for measuring depression. It assesses
depressed mood, vegetative and cognitive symptoms of de-
pression, and anxiety symptoms during the prior seven
days. Items are rated on either a five-point or a three-
point scale, and the total score is derived by summing the
individual item scores. Higher scores indicate greater
symptom severity. The HRSD has an interrater-reliability
of 0.90 [51] and shows high internal consistency (α = 0.88)
[52]. Furthermore, it is sensitive to change over time and
treatment and corresponds well with overall clinical rat-
ings of severity [53,54]. The cut-off points of 10, 19, 27,
and 35 represent the thresholds for mild, moderate, se-
vere, and very severe depression, respectively [52].Secondary outcomes
Depressive symptomatology Observer-based ratings of
depressive symptom severity will additionally be col-
lected using the 16-item Quick Inventory of Depressive
Symptomatology–Clinician-Rating (QIDS-CR16) [52] to
achieve a more nuanced understanding of the symptom
severity. The QIDS-CR16 is a brief clinician-report rating
scale developed from the 30-item Inventory of Depres-
sive Symptomatology [55,56]. Unlike the HRSD, the
QIDS-CR16 evaluates only the nine depression criterion
symptom domains (i.e., sad mood, concentration, self-
criticism, suicidal ideation, interest/involvement, energy/
fatigability, sleep disturbance, appetite/weight change,
and psychomotor agitation/retardation) from the Diag-
nostic and Statistical Manual of Mental Disorders (Fifth
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scored on a scale from 0 to 3 points, with higher scores
indicating higher symptom severity. This measure has
shown good psychometric properties, such as strong in-
ternal consistency (α = 0.85), concurrent validity, and
sensitivity to symptom change in patients with MDD
[56]. The cut-off points of 6, 11, 16, and 21 represent
the thresholds for mild, moderate, severe, and very se-
vere depression, respectively.
Self-reported depressive symptoms will be assessed with
the Patient Health Questionnaire (PHQ-9) [58]. This
measure has comparable sensitivity and specificity to
many other depression measures, although it is signifi-
cantly shorter than most other measures [59]. The internal
reliability of PHQ-9 reaches values between α = 0.86 and
0.89. The score ranges from 0 to 27 because each of the
nine items can be scored from 0 (“not at all”) to 3 (“nearly
every day”). The cut-off points of 5, 10, 15, and 20 repre-
sent the thresholds for mild, moderate, moderately severe,
and severe depression, respectively [58,59].Quality of life Health-related quality of life will be mea-
sured with the generic EuroQol [60]. The EuroQol in-
cludes the EQ-5D and a visual analogue scale. The EQ-5D
consists of five items covering five dimensions (mobility,
self-care, usual activities, pain/discomfort, and anxiety/de-
pression). The items are rated as causing “no problems”,
“some problems”, or “extreme problems”. This question-
naire shows good psychometric properties in terms of val-
idity and reliability in Germany [61].Problem-solving skills Problem-solving ability (i.e.,
generalised appraisal, beliefs, expectancies, and emo-
tional responses) will be measured with two subscales of
the Social Problem-Solving Inventory-Revised (SPSI-R)
[60]. The positive problem orientation (PPO) subscale
represents a constructive dimension, whereas the nega-
tive problem orientation (NPO) subscale is viewed as a
dysfunctional dimension. Both subscales demonstrate
strong psychometric properties. Cronbach’s alphas for
these subscales are α = 0.76 for the PPO dimension and
0.83 for the NPO dimension [62].Behavioural activation Participants’ activation towards
goals/values and pleasant activities as well as avoidance
behaviours will be measured with the BADS-Short Form
(BADS-SF) [63]. The BADS-SF includes nine items com-
prising two subscales (activation and avoidance). The
items are rated on a seven-point scale. Higher scores in-
dicate that the individual scores high on the area of
interest. The BADS-SF shows good psychometric prop-
erties. The internal consistency is α = 0.82 [63].Worrying Worrying will be assessed with the ultra-brief
version of the Penn State Worry Questionnaire (PSWQ)
[64]. This version consists of three items derived from the
standard version, with each item being rated on a seven-
point scale. The total score ranges from 0-18, with a
higher score indicating more worry. The ultra-brief ver-
sion shows similar psychometric properties as the stand-
ard version and an internal consistency of α = 0.85 [64].
Therapy expectations and helping alliance Therapy
expectations will be assessed with the Patient Question-
naire on Therapy Expectation and Evaluation (PATHEV)
[65], which includes the following three scales: hope for im-
provement, fear of change, and suitability. The items are
rated on a three-point-scale. The reliability of the scales has
been shown to be good to sufficient (α = 0.73-0.89) [65].
Therapeutic alliance will be measured with the Helping
Alliance Questionnaire (HAQ) [64]. This self-report ques-
tionnaire contains 11 items rated on a six-point-scale and
including two subscales: “helpfulness” and “cooperation”.
The scale exhibits excellent internal consistency (α = 0.89)
and test-retest reliability [66,67].
Response remission, and time to remission Based on
the recommendation of Rush (2006), we will use a defin-
ition of response/remission that reflects a clinically sig-
nificant benefit, depending on the specific setting and
needs in this trial [68]. A decline in the PHQ-9-score of
at least five points will be taken as a clinically significant
response. Remission in this specific context will be
understood as a symptom-free state, an absolute PHQ-
9-score of less than ten will be defined as partial remis-
sion, and a PHQ-9-score of less than five will be defined
as remission [58]. Time to remission will be defined as
the number of days until the symptom-free state is
achieved for the first time.
Statistical analyses
This clinical trial will be conducted in compliance with
the protocol of the Declaration of Helsinki and GCP.
Aiming at an intention-to-treat design we will include
all participants who will be randomly assigned to condi-
tions. Additional per protocol analyses (PPA) will be
conducted, including only participants’ satisfying proto-
col treatment.
Missing data will be handled using multiple imputa-
tions (MI). MI is especially robust with respect to miss-
ing data [69]. Nevertheless, to assess systematic effects
of missing data that cannot be ignored, pattern mixture
analyses for multi-level longitudinal approaches [70] will
be conducted. To determine whether the treatment ef-
fect is dependent on missing data, the missing-data pat-
tern of each participant will first be coded and then
included in a three-way interaction (missing-data pattern
Reins et al. BMC Psychiatry 2013, 13:318 Page 7 of 9
http://www.biomedcentral.com/1471-244X/13/318x condition x change in depression severity) in the main
outcome analyses. If no significant interactions between
the missing-data pattern and the treatment outcome are
found, it can be concluded that it is very unlikely that
missing data skewed the results.
The mean improvement scores on all continuous out-
come measures will be analysed within and between
groups via mixed-model analyses of variance. For all
mixed-model analyses, Cohen’s d [71] will be calculated
by standardising the differences between baseline and
follow-up scores by the pooled standard deviation of
baseline scores.
The clinically significant improvements between pre-
treatment and post-treatment will be examined with re-
gard to the definition of Kroenke (2002) [58]. Differences
in response and remission rates will be analysed using
chi-square tests. We will also calculate the number
needed to be treated (NNT) to achieve response, partial
remission, or remission. Time to remission will be mea-
sured in days, and the differences between groups in
time to remission will be compared using a t-test for in-
dependent samples.
Analyses will be performed using an alpha level of 0.05
and one-sided tests will be used for unidirectional and
two-sided tests for bidirectional hypotheses. All analyses
will be conducted using SPSS 21.
Discussion
Major depression is a prevalent and severe disorder. Sev-
eral circumstances lead to the fact that patients remain
untreated despite their urgent need for help. Web-based
treatments may be an appropriate way of bridging the
time gap for patients on a waiting list. Using waiting
time efficiently by introducing patients to upcoming
therapeutic components before the start of inpatient
therapy might be a promising approach to reduce the
burden of disease for the patients, to promote earlier
discharges and, as a result, to achieve shorter waiting
times for subsequent patients.
This study will probably contribute to the literature by
evaluating a new web-based intervention for depression
compared to treatment as usual in patients on a waiting
list for inpatient psychotherapy in a rater-blind rando-
mised controlled trial. We will (a) test the main hypothesis
that providing patients access to internet-based, guided
self-help will lead to reduced symptom severity before in-
patient treatment starts. Moreover, we will (b) investigate
whether patients achieve remission earlier and (c) whether
we can find significantly more patients with remission or
response at the end of inpatient treatment.
There are several strengths to this study: This study
will likely be one of the first randomised controlled stud-
ies that investigates a web-based intervention for pa-
tients on a waiting list for inpatient psychotherapy. Wewill also (a) use validated clinician-rated measures ad-
ministered by independent raters blind to treatment
condition in addition to self-report, (b) include a specific
sample defined by standard diagnostic measures, (c) im-
plement an appropriate statistical analysis plan, and (d)
use state-of-the-art methods to cope with missing data.
This trial has also several limitations: As the trial will be
conducted within the context of routine mental health
care, the time span between the post-treatment assess-
ment (conducted after the web-based treatment) and the
beginning of inpatient therapy depends on both the cap-
acities of the clinic and the eagerness of the patient and
therefore will vary between patients. We will assess post-
treatment data in both conditions at three weeks after ran-
domisation to ensure a comparable time frame. Hence, pa-
tients will be at varying states within the online training
when the post-treatment assessment takes place. Further-
more, we chose not to include a placebo/attention control
condition because the TAU condition cannot be fore-
known and is expected to be quite heterogeneous. Besides
it is our aim is to study the effectiveness of GET.ON
Mood Enhancer-WL in addition to and compared with
usual care, as is standard in pragmatic trials [72]. However,
due to the lack of such an active control condition, the
mechanisms responsible for any possible effects will re-
main unclear. Last, we will include follow-up assessments
only until the end of inpatient treatment. Therefore, we
cannot draw conclusions about the effects on the long-
term course of symptoms.
In the long term, it would be a desirable step to in-
creasingly implement a new procedure such as this into
the daily routine of inpatient as well as outpatient ther-
apy. It would be good practice for the therapist to know
in detail what steps the patient has taken previously and
to be able to continue the previous gains. This know-
ledge would assist both the patient and the therapist,
saving time and effort, and allowing them to concentrate
on further issues and to intensify the treatment process.
Future research could make use of a homogenous con-
trol group, focus on various modifications of the pro-
gram to identify active ingredients, compare different
interventions that are likely to be effective as pre-
inpatient treatments, evaluate web-based interventions
for other disorders than depression or change the setting
into the field of outpatient therapy.
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